Informed Prostate Cancer Patient Support

Scientists find a new weakness in treatment-resistant prostate cancer | ScienceDaily IPCSG  Informed Prostate Cancer Support Group Research Update - Treatment Resistance · Precision Medicine A New Drug-Pairing Strategy for Treatment-Resistant Prostate Cancer When prostate cancer changes its identity to dodge hormone therapy, one drug may not be enough. A University of Michigan team makes the case for hitting the disguise from both directions at once. Prepared for the IPCSG Newsletter  •  September 2026 Bottom Line Up Front Some advanced prostate cancers escape hormone-blocking drugs by physically changing what kind of cell they are — a process called transdifferentiation or lineage plasticity . Researchers at the University of Michigan Rogel Cancer Center report that this escape has two moving parts, and that pairing two classes of “epigenetic” drugs — a BET bromodomain inhibitor and a DNMT inhibitor — blocked both parts and slowed tumo...

Differential Radiobiological Effects of Αlpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival - International Journal of Radiation Oncology, Biology, Physics How to Make It Work at Lower Doses An IPCSG Newsletter feature on the radiobiology behind Pluvicto, Actinium-225, and the next wave of radioligand therapy. The author is a participant in a current Actinium 225 trial at UCSD Health Moores Cancer Center after having failed on Pluvicto. Bottom Line Up Front Targeted radionuclide therapy (TRT) — the class of treatment that includes the FDA-approved drug Pluvicto — delivers radiation directly to prostate cancer cells by riding on a molecule that locks onto PSMA , a protein studded on the surface of most prostate tumors. Two "payload" radioisotopes dominate the field: lutetium-177 (a beta-minus emitter, already approved) and actinium-225 (an alpha emitter, still investigational). A newly reported laboratory study from the German Cancer ...

The Clues Hidden in Failed Prostate Cancer Trials IPCSG Newsletter  •  Treatment Advances What the “Failures” Are Finally Teaching Us A patient-friendly review of the science — Summer 2026 BLUF (Bottom Line Up Front):    For fifteen years, the checkpoint-inhibitor drugs that revolutionized melanoma, lung, and kidney cancer failed one prostate-cancer trial after another — six large Phase 3 studies came back negative. But hidden inside those “failures” was a small group of men who had dramatic, lasting remissions. By studying those rare responders one cell at a time, researchers have now identified why most prostate tumors resist immunotherapy (immune-suppressing “SPP1” macrophages) and what lets a few tumors melt away (unusual killer T-cell populations). Today, only men whose tumors carry specific genetic signatures — mismatch-repair deficiency (dMMR), high microsatellite instability (MSI-H), or high tumor mutational burden (TMB) — have an FD...

Researchers Uncover a Promising New Way To Stop Prostate Cancer From Spreading IPCSG Newsletter ● Research Watch Informed Prostate Cancer Support Group  |  Treatment Advances Swedish and international researchers report a laboratory-stage drug that blocks the molecular signal aggressive prostate cancer uses to invade and metastasize—while leaving healthy signaling untouched. A patient-focused summary of Flodbring Larsson et al., Signal Transduction and Targeted Therapy , published June 17, 2026. BLUF — Bottom Line Up Front Researchers at Umeå University (Sweden), with collaborators in London and Uppsala, engineered a fully human antibody called mAbF11 that targets a receptor, TβRI , which aggressive prostate cancer cells hijack to spread. In laboratory cells and in mice, the antibody shrank tumors and blocked metastasis to lymph nodes —working about as well as docetaxel chemotherapy, but without the weight lo...